A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19. (2022)

First Author: Fowotade A
Attributed to:  New Branched Polymers Excipients and Emulsions for Enhanced Drug Delivery funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3389/fmed.2022.956123

PubMed Identifier: 36160134

Publication URI: http://europepmc.org/abstract/MED/36160134

Type: Journal Article/Review

Volume: 9

Parent Publication: Frontiers in medicine

ISSN: 2296-858X